Full Breakdown
FDA Approves First OTC Combination of Acetaminophen and Naproxen
8/1/2026, 10:46:40 AM
Regulatory Approval
The Food and Drug Administration has granted over-the-counter status to a new pain medication that merges the active ingredient in Tylenol (acetaminophen) with the active ingredient in Aleve (naproxen sodium). Marketed as Tylenol with Naproxen, the product is slated for release in the United States and will be sold to adults and children aged 12 years and older for temporary relief of minor aches such as headaches, backaches, muscle aches, toothaches, menstrual cramps, and mild arthritis pain.
Background and Product Details
Kenvue, the parent company of Tylenol, developed the fixed-dose combination to offer both rapid onset and extended duration in a single tablet. The agency noted that the approval aligns with the Trump administration’s “Great Healthcare Plan,” which aims to broaden access to safe OTC medicines. Kenvue received three years of market exclusivity for the formulation.
Data and Clinical Findings
Eight clinical studies cited by Kenvue demonstrated that the combination provides superior pain relief compared with acetaminophen alone or naproxen sodium alone. The product is reported to begin working within 30 minutes and to maintain analgesic effect for up to 12 hours. The FDA’s labeling specifies use for minor aches and pains in adults and children twelve years of age or older.
Official Statements & Responses
Dr. Rajesh Mishra, chief medical officer at Kenvue, said the approval reflects Tylenol’s long-standing leadership in translating rigorous clinical science into accessible OTC solutions. The FDA emphasized that the medication simplifies treatment choices for persistent pain by pairing fast onset with a 12-hour duration while retaining the safety profile of two well-established non-opioid ingredients.
Verbatim Quotes
- “This milestone reflects the long-standing leadership of Tylenol in translating rigorous clinical science into accessible, over-the-counter solutions,” — Dr. Rajesh Mishra, chief medical officer at Kenvue
- “Persistent pain often leaves people trapped in a cycle of trial and error, navigating between choosing short-term relief or more complex treatment options. Tylenol with Naproxen simplifies that choice, offering fast onset, 12-hour duration and the safety profile of two well-established non-opioid ingredients in one fixed-dose.” — The FDA
